Saturday, September 23, 2023
Saturday, September 23, 2023

Philips Integrates MedChat’s AI Capabilities to Optimize Automated Patient Communication & Hospital Workflows

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a collaboration with USA-based MedChat to integrate MedChat’s live chat and AI-driven chatbot services into Philips Patient Navigation Manager, helping improve call center efficiency and speed the time to resolve patient inquiries.

With the combined offering, Philips now enables its customers in North America to create automated communication workflows that function seamlessly alongside patient access and call center operations. Hospitals and outpatient clinics can also digitally navigate patients from the time an order is placed, to when it is scheduled and completed through follow-up.

Patient Navigation Manager automatically guides patients through their care journey using HIPAA-compliant SMS, email, and voice messages. With the new MedChat capabilities, patients now have the ability to perform complex tasks by linking directly with live agents using MedChat’s advanced chatbot services. Medchat’s natural language processing (NLP) reads and understands patients’ messages, while its machine learning algorithms adapt over time to provide the most relevant information. It’s symptom checker and triage bot – now embedded within Patient Navigation Manager’s core communications technologies – evaluates 125,000 evidence-based references to diagnose patients and recommend the appropriate care setting.

Since its introduction a year ago, Philips Patient Navigation Manager has experienced widespread adoption among health systems in the USA, generating early success for customers including an 86% reduction in same-day cancellations [1], a 45% reduction in no-shows [2], and a 30% increase in referral conversion efficiency [3]. Philips Patient Navigation Manager easily scales across the enterprise, and is conveniently accessible through a mobile device or computer without the need for patients to download an app.  

“Philips continues to demonstrate our ongoing commitment and leadership in patient management and engagement with fully integrated solutions into our suite of smart connected imaging systems,” said Brent Berthy, General Manager of Precision Diagnosis Solutions at Philips. “By combining MedChat’s technology with Philips Patient Navigation Manager, we can help healthcare enterprises deliver streamlined diagnostic workflows that meet the quadruple aim of better patient outcomes, enhanced patient and staff experiences, and lower operational costs due to the elimination of burdensome manual outreach task.”

“Philips Patient Navigation Manager does a great job helping providers communicate with patients while improving outcomes, while MedChat helps make that HIPAA-compliant conversation two-way, real-time, and an enhanced experience,” said Matt Yagey, Founder and CEO at MedChat. “We are excited to bring our integrated solution to Philips customers and also see an enormous need for Patient Navigation Manager among our hundreds of customers.”

The Philips-Medchat collaboration follows a similar enhancement to digitally connect patients to practitioners outside the hospital or clinic. Earlier this year, Philips teamed with openDoctor to integrate real-time patient self-scheduling capabilities into Philips Patient Navigation Manager. The customizable, single-vendor solution for radiology patient management aims to reduce lost slots, improve speed of scheduling, optimize appointment preparation, and improve patient and staff satisfaction.

Philips Patient Navigation Manager, a Software-as-a-Service (SaaS) offering, will be highlighted at this year’s Radiological Society of North America (RSNA) Annual Meeting (November 28 – December 2, 2021, Chicago, U.S.A.). Join Philips at RSNA 2021 where the company will spotlight its latest portfolio of radiology workflow solutions and smart connected imaging systems to increase efficiency and diagnostic confidence in precision care and treatment, and follow @PhilipsLiveFrom for updates throughout RSNA.


[1] Balakrishnan AS, Nguyen HG, Shinohara K, Au Yeung R, Carroll PR, Odisho AY. A Mobile Health Intervention for Prostate Biopsy Patients Reduces Appointment Cancellations: Cohort Study. Journal of medical Internet research. 2019;21(6):e14094.12
[2] Solonowicz O, Stier MW, Kim K, Kupfer SS, Sengupta N. 860 Digital Navigation Improves No Show Rates and Bowel Preparation Quality for Patients Undergoing Colonoscopy – A Randomized Controlled Study. Gastroenterology. 2020;158(6):S-176.13
[3] Feng A, Elias J, Hart K, Roberts P, Laskowski K. Automated Patient Navigation Platform Increases Referral Conversion for Surgical Consultations. Paper presented at: Connected Health Conference 2018; Boston, MA.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase...

The EV-302 study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), compared to chemotherapy. An Independent Data Monitoring Committee determined that OS crossed the pre-specified efficacy boundary at interim analysis. The safety results of the combination are consistent with those of enfortumab vedotin in combination with pembrolizumab previously reported in cisplatin-ineligible patients with la/mUC.

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

"Dosing the first patient, on time, is a testament to our commitment to the clinical development of DA-1241 in patients with NASH," stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. "Based on the pre-clinical and clinical evidence generated to date, DA-1241 has demonstrated reduced hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control, and was shown to be well tolerated in both healthy volunteers and in patients with type 2 diabetes mellitus (T2DM). Given this data, we believe that the mechanism of action of this promising cardiometabolic asset will translate into a safe and effective treatment for NASH, a disease with no current treatment options. The two-part design of this trial provides optionality for a potential interim analysis in the first half of 2024 and we expect to report the full data in the second half of 2024."

Medmain Inc. Has Been Selected for the U.S. Market Gateway Accelerator for BioSciences and MedTech

The "U.S. Market Gateway Accelerator for BioSciences and MedTech", sponsored by WorldUpstart, LLC, is an acceleration program that provides medical tech and life sciences startups with a proven track record outside the U.S. with the opportunity to enter and grow their business in the U.S. market.

Karger Publishers New Journal – Immune System

“Immune System is an innovative Open Access journal, welcoming articles with a broad background from basic science to clinical research, as long as the manuscript focuses on certain aspects of our immune response,” states editor-in-chief Désirée Larenas-Linnemann."

MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)

Robert Barrow, Chief Executive Officer and Director of MindMed. “Thanks in large part to the enthusiasm we have seen regarding MM-120 among investigators and patients, as well as the strong execution of our team, we were able to enroll almost 200 participants in this trial in just over a year. We anticipate sharing topline results during the fourth quarter of this year.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy